HK1146792A1 - Parp inhibitor compounds, compositions and methods of use parp - Google Patents

Parp inhibitor compounds, compositions and methods of use parp

Info

Publication number
HK1146792A1
HK1146792A1 HK11100918.6A HK11100918A HK1146792A1 HK 1146792 A1 HK1146792 A1 HK 1146792A1 HK 11100918 A HK11100918 A HK 11100918A HK 1146792 A1 HK1146792 A1 HK 1146792A1
Authority
HK
Hong Kong
Prior art keywords
parp
compositions
methods
inhibitor compounds
parp inhibitor
Prior art date
Application number
HK11100918.6A
Other languages
English (en)
Chinese (zh)
Inventor
Weizheng Xu
Greg Delahanty
Ling Wei
Jie Zhang
Original Assignee
Eisai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40526672&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1146792(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Inc filed Critical Eisai Inc
Publication of HK1146792A1 publication Critical patent/HK1146792A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK11100918.6A 2007-10-03 2011-01-28 Parp inhibitor compounds, compositions and methods of use parp HK1146792A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97711507P 2007-10-03 2007-10-03
PCT/US2008/078606 WO2009046205A1 (en) 2007-10-03 2008-10-02 Parp inhibitor compounds, compositions and methods of use

Publications (1)

Publication Number Publication Date
HK1146792A1 true HK1146792A1 (en) 2011-07-15

Family

ID=40526672

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11100918.6A HK1146792A1 (en) 2007-10-03 2011-01-28 Parp inhibitor compounds, compositions and methods of use parp

Country Status (28)

Country Link
US (3) US8236802B2 (xx)
EP (2) EP2842956A1 (xx)
JP (1) JP5439380B2 (xx)
KR (1) KR101596526B1 (xx)
CN (1) CN102083314B (xx)
AU (1) AU2008308664B2 (xx)
BR (1) BRPI0820518B1 (xx)
CA (1) CA2700903C (xx)
CL (1) CL2010000320A1 (xx)
CY (1) CY1115747T1 (xx)
DK (1) DK2209375T3 (xx)
ES (1) ES2504690T3 (xx)
HK (1) HK1146792A1 (xx)
HR (1) HRP20140853T1 (xx)
IL (1) IL204776A (xx)
JO (1) JO3170B1 (xx)
MX (1) MX2010003564A (xx)
MY (1) MY155237A (xx)
NZ (1) NZ585012A (xx)
PL (1) PL2209375T3 (xx)
PT (1) PT2209375E (xx)
RU (1) RU2485122C2 (xx)
SG (1) SG185272A1 (xx)
SI (1) SI2209375T1 (xx)
TW (1) TWI426912B (xx)
UA (1) UA99483C2 (xx)
WO (1) WO2009046205A1 (xx)
ZA (1) ZA201002317B (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007008771A (es) 2005-01-19 2007-09-11 Mgi Gp Inc Compuestos de diazabenzo [des] antracen-3-ona y metodos para inhibir parp.
JP5439380B2 (ja) 2007-10-03 2014-03-12 エーザイ インク. Parp阻害化合物、組成物及び使用方法
ES2625817T3 (es) * 2008-08-06 2017-07-20 Medivation Technologies, Inc. Inhibidores de tipo Dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP)
EP2322658A1 (en) 2009-11-13 2011-05-18 Centre National de la Recherche Scientifique (CNRS) Signature for the diagnosis of breast cancer aggressiveness and genetic instability
KR101826652B1 (ko) * 2010-02-08 2018-02-07 메디베이션 테크놀로지즈, 인크. 디히드로피리도프탈라지논 유도체의 합성 방법
DK3012329T3 (da) 2010-06-18 2017-11-20 Myriad Genetics Inc Fremgangsmåder og materialer til at vurdere tab af heterozygositet
US9649394B2 (en) 2010-11-22 2017-05-16 The General Hospital Corporation Compositions and methods for in vivo imaging
EP2683825B1 (en) * 2011-03-11 2017-01-04 Sarissa Inc. Methods of treating cancer by inhibition of dna repair proteins
TW201244714A (en) * 2011-04-11 2012-11-16 Abbott Lab PARP inhibitors for the treatment of CIPN
WO2012156501A1 (en) 2011-05-18 2012-11-22 Centre National De La Recherche Scientifique (Cnrs) Signature for the diagnosis of cancer aggressiveness and genetic instability
CN103781776A (zh) * 2011-07-13 2014-05-07 诺华股份有限公司 用作端锚聚合酶抑制剂的新的2-哌啶-1-基-乙酰胺化合物
WO2013028495A1 (en) * 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
AU2012358244A1 (en) * 2011-12-21 2014-06-12 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
US9790556B2 (en) 2012-01-05 2017-10-17 Centre National De La Recherche Scientifique (Cnrs) Signature for the diagnosis of lung cancer aggressiveness and genetic instability
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び/又は副作用を低減するための方法および組成物
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
CN106659765B (zh) 2014-04-04 2021-08-13 德玛医药 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途
JP6648040B2 (ja) * 2014-05-28 2020-02-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 がん治療のための併用療法としてのエリブリン及びポリ(adpリボース)ポリメラーゼ(parp)阻害剤の使用
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
US11261466B2 (en) 2015-03-02 2022-03-01 Sinai Health System Homologous recombination factors
CN104945406B (zh) * 2015-05-25 2017-10-10 苏州康润医药有限公司 氮杂非那烯‑3‑酮的衍生物、其制备方法及其作为parp抑制剂的应用
CN108138177B9 (zh) 2015-07-23 2021-08-13 法国居里学院 Dbait分子与PARP抑制剂的组合用于治疗癌症的用途
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018165615A1 (en) * 2017-03-09 2018-09-13 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Parp-1 and methods of use thereof
US20200230134A1 (en) * 2017-03-09 2020-07-23 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Parp-1 and methods of use thereof
US20200407720A1 (en) 2018-03-13 2020-12-31 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
KR20220079938A (ko) * 2019-10-10 2022-06-14 에스테베 파마슈티칼스 에스에이 통증에 대한 다중모드 활성을 갖는 호모피페라지닐 및 호모피페리디닐 퀴나졸린-4(3h)-온 유도체
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021249996A1 (en) 2020-06-08 2021-12-16 Oncology Venture ApS Compositions comprising 2x-121 and methods for treating coronavirus infection
CN114053276B (zh) * 2020-07-30 2024-05-07 江苏天士力帝益药业有限公司 一种parp抑制剂tsl-1502中间体tsl-1502m的用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041653A (en) 1985-05-03 1991-08-20 Sri International Substituted benzamide radiosensitizers
US5215738A (en) 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
US5032617A (en) 1985-05-03 1991-07-16 Sri International Substituted benzamide radiosensitizers
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
US6291425B1 (en) * 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
AU9298098A (en) 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
WO1999011644A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
US5950784A (en) 1997-09-03 1999-09-14 Yang; Shu-Chiung C. Hub structural improvement
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
CA2332279A1 (en) 1998-05-15 1999-11-25 Jia-He Li Carboxamide compounds, compositions, and methods for inhibiting parp activity
CA2332239A1 (en) 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
US6201020B1 (en) 1998-12-31 2001-03-13 Guilford Pharmaceuticals, Inc. Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
US6387902B1 (en) 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
SI20691B (sl) 1999-01-11 2008-10-31 Agouron Pharma Triciklični inhibitorji poli(ADP-riboza) polimeraz
WO2001057038A1 (de) 2000-02-01 2001-08-09 Basf Aktiengesellschaft Heterozyklische verbindungen und deren anwendung als parp-inhibitoren
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
DE10022925A1 (de) 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
CA2517629C (en) * 2003-03-12 2011-07-12 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7268138B2 (en) 2003-05-28 2007-09-11 Mgi Gp, Inc. Compounds, methods and pharmaceutical compositions for inhibiting PARP
MXPA05013145A (es) * 2003-06-10 2006-03-17 Hoffmann La Roche Derivados de 1,3,4-triaza-fenaleno y 1,3,4,6-tetraazafenaleno.
KR101138471B1 (ko) 2003-07-25 2012-04-25 화이자 인코포레이티드 트리시클로 parp 저해제
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
CN102107008B (zh) 2003-12-01 2013-04-03 库多斯药物有限公司 用于治疗癌症的dna损伤修复抑制剂
JP4964772B2 (ja) 2004-08-04 2012-07-04 フォスフォニックス リミテッド 置換有機ポリシロキサン類及びそれらの使用
MX2007008771A (es) * 2005-01-19 2007-09-11 Mgi Gp Inc Compuestos de diazabenzo [des] antracen-3-ona y metodos para inhibir parp.
JP5439380B2 (ja) 2007-10-03 2014-03-12 エーザイ インク. Parp阻害化合物、組成物及び使用方法
WO2009137411A1 (en) 2008-05-09 2009-11-12 Allergan, Inc. Therapeutic compounds
CN103097355A (zh) 2010-07-08 2013-05-08 惠氏有限责任公司 用于治疗皮肤病的新的喹啉酯

Also Published As

Publication number Publication date
US8236802B2 (en) 2012-08-07
NZ585012A (en) 2012-06-29
CN102083314B (zh) 2014-04-30
IL204776A (en) 2015-09-24
SG185272A1 (en) 2012-11-29
WO2009046205A1 (en) 2009-04-09
RU2010117397A (ru) 2011-11-10
AU2008308664B2 (en) 2014-07-17
RU2485122C2 (ru) 2013-06-20
PL2209375T3 (pl) 2014-12-31
IL204776A0 (en) 2010-11-30
EP2842956A1 (en) 2015-03-04
JP2010540655A (ja) 2010-12-24
JP5439380B2 (ja) 2014-03-12
EP2209375A4 (en) 2011-03-09
US20090098084A1 (en) 2009-04-16
MX2010003564A (es) 2010-09-10
CA2700903A1 (en) 2009-04-09
DK2209375T3 (da) 2014-10-06
US8894989B2 (en) 2014-11-25
US20150141429A1 (en) 2015-05-21
TW200932239A (en) 2009-08-01
ES2504690T3 (es) 2014-10-08
TWI426912B (zh) 2014-02-21
BRPI0820518A2 (pt) 2020-01-14
JO3170B1 (ar) 2017-09-20
KR20100100771A (ko) 2010-09-15
PT2209375E (pt) 2014-10-08
US20130011365A1 (en) 2013-01-10
CA2700903C (en) 2017-05-30
UA99483C2 (ru) 2012-08-27
HRP20140853T1 (hr) 2014-10-24
MY155237A (en) 2015-09-30
EP2209375A1 (en) 2010-07-28
ZA201002317B (en) 2013-09-25
BRPI0820518B1 (pt) 2021-09-28
KR101596526B1 (ko) 2016-02-22
CL2010000320A1 (es) 2011-03-11
EP2209375B1 (en) 2014-08-27
CN102083314A (zh) 2011-06-01
CY1115747T1 (el) 2017-01-25
SI2209375T1 (sl) 2014-12-31
AU2008308664A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
HK1146792A1 (en) Parp inhibitor compounds, compositions and methods of use parp
HUS1900009I1 (hu) Új vegyületek és készítmények, továbbá alkalmazási eljárásaik
HRP20160902T1 (hr) Pripravci i postupci uporabe forbolskih estera
IL210462A0 (en) Pyrimidine compounds, compositions and methods of use
IL196956A0 (en) Aza-benzofuranyl compounds and methods of use
IL184303A0 (en) Amino-pyridines as inhibitors of ??-secretase
PT2397142T (pt) Utilizações de inibidores da dpp iv
IL205142A0 (en) Pyridazinone derivatives as parp inhibitors
ZA200909152B (en) Triazolopyridine compounds and their use as ask inhibitors
IL197869A0 (en) Compositions of chk1 inhibitors
EP2211854A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING BENZOPYRONE-TYPE PARP INHIBITORS
IL197060A0 (en) Aza-benzothiophenyl compounds and methods of use
HK1137756A1 (en) Substituted dihydropyrazolones and use thereof as hif-prolyl-4 -hydroxylase inhibitors hif--4-
EP2217679A4 (en) TETRAFLUOROBORATE COMPOUNDS, COMPOSITIONS AND RELATED USES
ZA201007129B (en) Limk2 inhibitors,compositions comprising them,and methods of their use
IL200387A0 (en) Heterocylic compounds, compositions comprising them and methods of their use
ZA201000992B (en) Anti-viral compounds, compositions, and methods of use
IL205299A0 (en) Parp inhibitor compounds
ZA200900896B (en) Aza-benzofuranyl compounds and methods of use
ZA200901009B (en) Aza-benzothiophenyl compounds and methods of use
TH0801005083A (th) สารประกอบ องค์ประกอบ และกรรมวิธีการใช้ตัวยับยั้ง parp
GB0805693D0 (en) Combinations of P13-delta and P13-gamma kinase inhibitor compounds